Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Update on PARP Inhibitors in Breast Cancer.

Zimmer AS, Gillard M, Lipkowitz S, Lee JM.

Curr Treat Options Oncol. 2018 Apr 11;19(5):21. doi: 10.1007/s11864-018-0540-2. Review.

PMID:
29644491
2.

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.

Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, Kohn EC.

Lancet Oncol. 2018 Feb;19(2):207-215. doi: 10.1016/S1470-2045(18)30009-3. Epub 2018 Jan 18.

PMID:
29361470
3.

Analysis of breast cancer in young women in the Department of Defense (DOD) database.

Zimmer AS, Zhu K, Steeg PS, Wu A, Gatti-Mays ME, Soltani S, Perkins JG, Shao S, Brown D, Georg M, Hu H, Shriver CD, Lipkowitz S.

Breast Cancer Res Treat. 2018 Apr;168(2):501-511. doi: 10.1007/s10549-017-4615-8. Epub 2017 Dec 15.

PMID:
29247440
4.

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.

Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, Kohn EC.

Oncotarget. 2017 Mar 25;8(45):79175-79187. doi: 10.18632/oncotarget.16577. eCollection 2017 Oct 3.

5.

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.

Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, Swisher EM, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu H, Nguyen J, Ho TW, Figg WD, Kohn EC.

J Clin Oncol. 2017 Jul 1;35(19):2193-2202. doi: 10.1200/JCO.2016.72.1340. Epub 2017 May 4.

PMID:
28471727
6.

Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells.

Schardt JS, Oubaid JM, Williams SC, Howard JL, Aloimonos CM, Bookstaver ML, Lamichhane TN, Sokic S, Liyasova MS, O'Neill M, Andresson T, Hussain A, Lipkowitz S, Jay SM.

Mol Pharm. 2017 Apr 3;14(4):1047-1056. doi: 10.1021/acs.molpharmaceut.6b00919. Epub 2017 Mar 8.

7.

Mathematical models of breast and ovarian cancers.

Botesteanu DA, Lipkowitz S, Lee JM, Levy D.

Wiley Interdiscip Rev Syst Biol Med. 2016 Jul;8(4):337-62. doi: 10.1002/wsbm.1343. Epub 2016 Jun 3. Review.

8.

New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.

Yang SX, Polley E, Lipkowitz S.

Cancer Treat Rev. 2016 Apr;45:87-96. doi: 10.1016/j.ctrv.2016.03.004. Epub 2016 Mar 9. Review.

PMID:
26995633
9.

ONC201: Stressing tumors to death.

Endo Greer Y, Lipkowitz S.

Sci Signal. 2016 Feb 16;9(415):fs1. doi: 10.1126/scisignal.aad7955. Review.

PMID:
26884598
10.

The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.

Dine JL, O'Sullivan CC, Voeller D, Greer YE, Chavez KJ, Conway CM, Sinclair S, Stone B, Amiri-Kordestani L, Merchant AS, Hewitt SM, Steinberg SM, Swain SM, Lipkowitz S.

Breast Cancer Res Treat. 2016 Jan;155(2):235-51. doi: 10.1007/s10549-015-3673-z. Epub 2016 Jan 12.

11.

Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.

Li M, Kales SC, Ma K, Shoemaker BA, Crespo-Barreto J, Cangelosi AL, Lipkowitz S, Panchenko AR.

Cancer Res. 2016 Feb 1;76(3):561-71. doi: 10.1158/0008-5472.CAN-14-3812. Epub 2015 Dec 16.

12.

To Treat or Not to Treat: The Use of Hormone Replacement Therapy in Patients With Ovarian Cancer.

Lipkowitz S, Kohn EC.

J Clin Oncol. 2015 Dec 10;33(35):4127-8. doi: 10.1200/JCO.2015.63.6670. Epub 2015 Oct 5. No abstract available.

PMID:
26438113
13.

TIC10/ONC201: a bend in the road to clinical development.

Greer YE, Lipkowitz S.

Oncoscience. 2015 Feb 20;2(2):75-6. eCollection 2015. No abstract available.

14.

Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.

Liyasova MS, Ma K, Lipkowitz S.

Clin Cancer Res. 2015 Apr 15;21(8):1789-94. doi: 10.1158/1078-0432.CCR-13-2490. Epub 2014 Dec 4. Review.

15.

Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.

Garimella SV, Gehlhaus K, Dine JL, Pitt JJ, Grandin M, Chakka S, Nau MM, Caplen NJ, Lipkowitz S.

Breast Cancer Res. 2014 Apr 17;16(2):R41. doi: 10.1186/bcr3645.

16.

Recruitment of Cbl-b to B cell antigen receptor couples antigen recognition to Toll-like receptor 9 activation in late endosomes.

Veselits M, Tanaka A, Lipkowitz S, O'Neill S, Sciammas R, Finnegan A, Zhang J, Clark MR.

PLoS One. 2014 Mar 20;9(3):e89792. doi: 10.1371/journal.pone.0089792. eCollection 2014.

17.

E3 ubiquitin ligase Cbl-b suppresses proallergic T cell development and allergic airway inflammation.

Qiao G, Ying H, Zhao Y, Liang Y, Guo H, Shen H, Li Z, Solway J, Tao E, Chiang YJ, Lipkowitz S, Penninger JM, Langdon WY, Zhang J.

Cell Rep. 2014 Feb 27;6(4):709-23. doi: 10.1016/j.celrep.2014.01.012. Epub 2014 Feb 6.

18.

Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A.

Kales SC, Nau MM, Merchant AS, Lipkowitz S.

PLoS One. 2014 Jan 23;9(1):e87116. doi: 10.1371/journal.pone.0087116. eCollection 2014.

19.

Cbl-c ubiquitin ligase activity is increased via the interaction of its RING finger domain with a LIM domain of the paxillin homolog, Hic 5.

Ryan PE, Kales SC, Yadavalli R, Nau MM, Zhang H, Lipkowitz S.

PLoS One. 2012;7(11):e49428. doi: 10.1371/journal.pone.0049428. Epub 2012 Nov 7.

20.

E3 ubiquitin ligase Cbl-b regulates Pten via Nedd4 in T cells independently of its ubiquitin ligase activity.

Guo H, Qiao G, Ying H, Li Z, Zhao Y, Liang Y, Yang L, Lipkowitz S, Penninger JM, Langdon WY, Zhang J.

Cell Rep. 2012 May 31;1(5):472-82.

21.

Cbl exposes its RING finger.

Kales SC, Ryan PE, Lipkowitz S.

Nat Struct Mol Biol. 2012 Feb 3;19(2):131-3. doi: 10.1038/nsmb.2241. No abstract available.

PMID:
22301873
22.

WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis.

Garimella SV, Rocca A, Lipkowitz S.

Mol Cancer Res. 2012 Jan;10(1):75-85. doi: 10.1158/1541-7786.MCR-11-0500. Epub 2011 Nov 23.

23.

RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.

Lipkowitz S, Weissman AM.

Nat Rev Cancer. 2011 Aug 24;11(9):629-43. doi: 10.1038/nrc3120. Review.

24.

Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.

Chavez KJ, Garimella SV, Lipkowitz S.

Breast Dis. 2010;32(1-2):35-48. doi: 10.3233/BD-2010-0307. Review. No abstract available.

25.

ARAP1 association with CIN85 affects epidermal growth factor receptor endocytic trafficking.

Yoon HY, Kales SC, Luo R, Lipkowitz S, Randazzo PA.

Biol Cell. 2011 Apr;103(4):171-84. doi: 10.1042/BC20100154.

26.

The N terminus of Cbl-c regulates ubiquitin ligase activity by modulating affinity for the ubiquitin-conjugating enzyme.

Ryan PE, Sivadasan-Nair N, Nau MM, Nicholas S, Lipkowitz S.

J Biol Chem. 2010 Jul 30;285(31):23687-98. doi: 10.1074/jbc.M109.091157. Epub 2010 Jun 4.

27.

Cbl and human myeloid neoplasms: the Cbl oncogene comes of age.

Kales SC, Ryan PE, Nau MM, Lipkowitz S.

Cancer Res. 2010 Jun 15;70(12):4789-94. doi: 10.1158/0008-5472.CAN-10-0610. Epub 2010 May 25. Review.

28.

CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.

Tan YH, Krishnaswamy S, Nandi S, Kanteti R, Vora S, Onel K, Hasina R, Lo FY, El-Hashani E, Cervantes G, Robinson M, Hsu HS, Kales SC, Lipkowitz S, Karrison T, Sattler M, Vokes EE, Wang YC, Salgia R.

PLoS One. 2010 Jan 29;5(1):e8972. doi: 10.1371/journal.pone.0008972. Erratum in: PLoS One. 2011;6(1). doi: 10.1371/annotation/940edb14-522e-4f38-b6c4-7557e9a13d15. Hsu, Han-Shui [added].

29.

The TRAIL to targeted therapy of breast cancer.

Rahman M, Pumphrey JG, Lipkowitz S.

Adv Cancer Res. 2009;103:43-73. doi: 10.1016/S0065-230X(09)03003-6. Review.

30.

Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome.

Murrow LM, Garimella SV, Jones TL, Caplen NJ, Lipkowitz S.

Breast Cancer Res Treat. 2010 Jul;122(2):347-57. doi: 10.1007/s10549-009-0571-2. Epub 2009 Oct 10.

31.

Pümpfrage redivivus.

Stone B, Lipkowitz S.

JAMA. 2009 Aug 12;302(6):626; author reply 626. doi: 10.1001/jama.2009.1103. No abstract available.

PMID:
19671903
32.

2-methoxyestradiol mediates apoptosis through caspase-dependent and independent mechanisms in ovarian cancer cells but not in normal counterparts.

Kato S, Sadarangani A, Lange S, Delpiano AM, Vargas M, Brañes J, Carvajal J, Lipkowitz S, Owen GI, Cuello MA.

Reprod Sci. 2008 Nov;15(9):878-94. doi: 10.1177/1933719108324171.

PMID:
19050321
33.

TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype.

Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, Meltzer PS, Lipkowitz S.

Breast Cancer Res Treat. 2009 Jan;113(2):217-30. doi: 10.1007/s10549-008-9924-5. Epub 2008 Feb 12.

34.

Structural basis for ubiquitin-mediated dimerization and activation of the ubiquitin protein ligase Cbl-b.

Peschard P, Kozlov G, Lin T, Mirza IA, Berghuis AM, Lipkowitz S, Park M, Gehring K.

Mol Cell. 2007 Aug 3;27(3):474-85.

35.

PPARgamma agonists follow an unknown TRAIL in lung cancer.

Lipkowitz S, Dennis PA.

Cancer Biol Ther. 2007 Jan;6(1):107-9. No abstract available.

PMID:
17224637
36.

TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract.

Sadarangani A, Kato S, Espinoza N, Lange S, Llados C, Espinosa M, Villalón M, Lipkowitz S, Cuello M, Owen GI.

Apoptosis. 2007 Jan;12(1):73-85. Erratum in: Apoptosis. 2007 Feb;12(2):463.

PMID:
17136491
37.

EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins.

Davies GC, Ryan PE, Rahman L, Zajac-Kaye M, Lipkowitz S.

Oncogene. 2006 Oct 19;25(49):6497-509. Epub 2006 May 15.

38.

Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.

Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC, Lipkowitz S, Husain AN, Salgia R, Ma PC.

Nat Clin Pract Oncol. 2006 Jan;3(1):50-7; quiz 1 p following 57.

PMID:
16407879
39.

Regulating the regulator: negative regulation of Cbl ubiquitin ligases.

Ryan PE, Davies GC, Nau MM, Lipkowitz S.

Trends Biochem Sci. 2006 Feb;31(2):79-88. Epub 2006 Jan 6. Review.

PMID:
16406635
40.

Epidermal growth factor receptor expression in breast cancer.

Karlin JD, Nguyen D, Yang SX, Lipkowitz S.

J Clin Oncol. 2005 Nov 1;23(31):8118-9; author reply 8119-20. No abstract available.

PMID:
16258112
41.

Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer.

Calzone KA, Prindiville SA, Jourkiv O, Jenkins J, DeCarvalho M, Wallerstedt DB, Liewehr DJ, Steinberg SM, Soballe PW, Lipkowitz S, Klein P, Kirsch IR.

J Clin Oncol. 2005 May 20;23(15):3455-64.

PMID:
15908654
42.

Apoptosis and the treatment of breast cancer.

Cuello MA, Nau M, Lipkowitz S.

Breast Dis. 2002;15:71-82.

PMID:
15687647
43.

Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl).

Zeng S, Xu Z, Lipkowitz S, Longley JB.

Blood. 2005 Jan 1;105(1):226-32. Epub 2004 Aug 17.

44.

Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.

Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, Parr AL, Figg WD, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo JA, Brahim JS, Ettenberg SA, Lipkowitz S, Swain SM.

J Clin Oncol. 2004 Aug 1;22(15):3080-90.

PMID:
15284258
45.

Cbl-b interacts with ubiquitinated proteins; differential functions of the UBA domains of c-Cbl and Cbl-b.

Davies GC, Ettenberg SA, Coats AO, Mussante M, Ravichandran S, Collins J, Nau MM, Lipkowitz S.

Oncogene. 2004 Sep 16;23(42):7104-15.

PMID:
15273720
47.

Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme.

Rahman L, Voeller D, Rahman M, Lipkowitz S, Allegra C, Barrett JC, Kaye FJ, Zajac-Kaye M.

Cancer Cell. 2004 Apr;5(4):341-51.

48.

N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines.

Cuello M, Coats AO, Darko I, Ettenberg SA, Gardner GJ, Nau MM, Liu JR, Birrer MJ, Lipkowitz S.

Cell Death Differ. 2004 May;11(5):527-41.

49.

Cbl-3-deficient mice exhibit normal epithelial development.

Griffiths EK, Sanchez O, Mill P, Krawczyk C, Hojilla CV, Rubin E, Nau MM, Khokha R, Lipkowitz S, Hui CC, Penninger JM.

Mol Cell Biol. 2003 Nov;23(21):7708-18.

50.

WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation.

Magnifico A, Ettenberg S, Yang C, Mariano J, Tiwari S, Fang S, Lipkowitz S, Weissman AM.

J Biol Chem. 2003 Oct 31;278(44):43169-77. Epub 2003 Aug 7.

Supplemental Content

Loading ...
Support Center